WT VPS35 was recently shown to protect against neuronal toxicity induced by the mitochondrial Complex-I inhibitor, MPP+ (26), as well as against G2019S LRRK2 overexpression or RAB7L1 deficiency (27), two models relevant to familial PD. Here, LRRK2 is linked to Parkinson disease.